Avadel Pharmaceuticals plc (AVDL) Presents at Morgan Stanley 23rd Annual Global Healthcare

Company Overview - Avadel is a growing biotech company that has transformed itself over the past five years [3] - The company is currently in its ninth quarter of launching LUMRYZ, a once-at-bedtime oxybate for treating narcolepsy, with over 3,100 patients currently on the medication [4] Financial Performance - Avadel has achieved a cash flow positive state as a commercial stage organization [5] - The company is in the latter stages of a pivotal Phase III trial for expanding indications to include idiopathic hypersomnia [5]